IL1B and atherosclerosis: The importance of decreasing these inflammatory cytokines to protect against CVD is supported by data from the CANTOS study where targeting IL-1β with the canakinumab-blocking antibody induced a decrease in atherosclerosis and adverse cardiac events (62).